Talazoparib treats the cells of myelodysplastic syndromes
To determine the mechanistic origins of the SRSF2-mutant-selective effects of Talazoparib, we analyzed transcriptional changes after 2 d of Talazoparib treatment in SRSF2(P95H) mutant MDS-L cell by mRNA sequencing.